BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients

Inclusion Criteria: * Male or female patient with histological confirmation of NMIBC * Full recovery from surgery (TUR) from 1 to 6 weeks * Karnofsky performance status of 60% or more * Laboratory parameters for vital functions should be in the normal range * Women of childbearing potential must use adequate contraception and have negative pregnancy test before and during the whole period of study treatment administration * Male patients should avoid behaviors leading to child conception up to 2 months after administration of study treatment Exclusion Criteria: * Muscle invasive bladder cancer * Metastatic disease to the central nervous system, for which other therapeutic options, including radiotherapy, may be available * Other serious illnesses (e.g., serious infections requiring antibiotics, bleeding disorders) * Any confirmed or suspected immunosuppressive or immunodeficient condition or potential immune-mediated diseases(Patients with vitiligo are not excluded to participate in the trial) * History of severe allergic reactions to vaccines or unknown allergens * Patients require concomitant chronic treatment with systemic corticosteroids or any other immunosuppressive agents. The use of prednisone, or equivalent, \<0.125 mg/kg/day (absolute maximum 10 mg/day), or inhaled corticosteroids or topical steroids is permitted * Participation in any other clinical trial involving another investigational agent within 4 weeks prior to first dosing of study agent * Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study * Lack of availability for immunological and clinical follow-up assessment * For female patients of childbearing potential: positive urine or serum pregnancy test or lactating * Known positive HIV test, HBV, HCV.